A 2018 literature review summarizes the various ways patients can consume cannabis (orally, topically, etc.) and the pain reductions associated with each method. The review focuses on the treatment of multiple sclerosis, cancer, anorexia, arthritis, and other painful disorders.
A 2019 literature review summarizes the finding on using THC and CBD on patients with dementia. Researchers found that Dronabinol and THC were associated with significant improvements in a range of psychiatric scores. Interestingly, cannabis products showed the most promising results in patients whose symptoms were previously unmanageable or resistant to other treatments.
Human study finds that, when taken with opioids, dronabinol (THC) may increase impairment and decrease, or not affect, pain relief. Researchers conclude that THC might NOT protect the body from the adverse effects of opioids. However, the study examined only 10 participants, and such a small sample size should give pause to the validity and applicability of the findings.
Study provides rigorous data to support clinical evaluation of THC as a low-toxic therapy option in acute leukemia patients. In related work, full-spectrum, natural derivatives of cannabis may work more effectively than their pharmaceutical counterparts.
Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement
Obstructive sleep apnea is a sleep disorder causing episodic airway obstruction that results in the brief “apneic” (cessation of breathing) episodes for brief periods of time. A recent study investigating Dronabinol, a synthetic cannabis derivative, as a potential therapy for sleep apnea resulted in an improvement of 32% in the apnea-hypopnea index. However, the American Academy of Sleep Medicine does not endorse medical cannabis as a treatment for sleep apnea, due to what they point to as a lack of knowledge surrounding the long-term effects of its use. ” Based on these results, cannabis and its components should be further researched to determine its potential for sleep apnea treatment.
Dronabinol-Induced Hypomania: A Case Report and Literature Review
An HIV patient who also suffers from bipolar disorder was administered dronabinol, a synthetic cannabis alternative. Following a dosage increase, the previously stable patient presented to his psychiatrist in a state of hypomania. Although this singular case study cannot be used to make any definitive conclusion, it underscores the need for further research surrounding the effects of cannabis on mood